Grant: Discovery Grants Program - Individual
Université Laval
$22,000.00
Smart Medical Instrumentation On Chips For Early Detection and Treatment of Brain Molecular Disorder
EF 2014-15
Résumé
Major advances in medicine, drug discovery and new treatments can considerably improve the quality of life of the world population. On the other hand, new diseases are surfacing and affecting the 65 years and plus population. Most of these health problems are associated with neurodegenerative diseases, which are mainly related to a neurotransmitter (NT) concentration disorder in the brain. Alzheimer?s is one of neurodegenerative diseases that affect the largest portion of the world?s elderly population. The Alzheimer?s society of Montreal estimates that the number of patient suffering from this disease will be 34 million worldwide in 2025 and will reach a total of 750 000 patients in Canada in 2031. Up to now, there is no treatment for Alzheimer?s disease, but there are several alternatives to reduce its impact and effects. Our discovery proposal will offer hope for patients suffering from this disease by controlling the neurotransmitters (NTs) concentration in a local area of the brain in order to stop the disorder caused by Alzheimer?s using miniaturized and implantable microsystems. Indeed, NTs are among the most important information vehicles in the brain. Almost all human behavior and body functions are monitored by NTs and any disorder due to these molecules will affect our quality of life and health conditions. Our recently published results show that the electrical properties of cerebrospinal fluid (CSF) are affected by the NTs concentration. We have identified a relation between CSF impedance, conductivity and NTs concentration. Finally, we have proven with glutamate NT and gamma amino butyric acid (GABA) NT that the CSF impedance and conductivity are affected by the change of NTs concentration. As an example, Alzheimer?s disease is related to a considerable decrease of acetylcholine NT which affects CSF properties based on our previous research. Furthermore, as the concentration of NTs can be in the range of sub-nano liters, we need an extremely highly sensitive device with an accuracy of 0.001 S/m and 10 ohm to measure the conductivity and resistivity of the CSF, respectively. An innovative contribution of this work is the establishment of a new perspective for the analysis of brain neuronal activities where one assumes that NTs (acetylcholine, dopamine and GABA) can be differentiated based on their concentration, impedance and/or conductivity. If successful, this could provide an important alternative to the current treatment of patients with neurodegenerative diseases such as Alzheimer?s. We are proposing a new generation of brain implantable devices that are sensing the chemical and molecular brain activity and can also achieve neurotransmitter local delivery in order to stop brain disorder. In order to achieve this objective, we propose a medical instrumentation on-chip (MIOC) to sense and modulate NT concentration in limited area. This discovery covers the following aspects of MIOC design: 1- Development of a new fabrication process to design microelectrode for NTs sensing and manipulation and biosensing techniques for NTs based on carbon nanotubes. 2- Design and Implementation of highly sensitive microelectronics circuit to detect NT concentration change 3- Development of a new in-channel and air bubble liquid sampling technique to sample a few nano-liters of NT. Such a technique, will certainly open other alternatives to replace conventional micro pumps as it does not require any dedicated microfabrication process. The proposed MIOC can also be generalized for blood chemical and molecular disorders such as for cholesterol, sickle-cell anemia, etc. as the sensing and liquid manipulation architecture are the same while the bio-interface differs from one application to another.
Programme
Discovery Grants Program - Individual
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
RGPIN-2014-05603
Name nom
Miled, Amine
Department département
Electrical and Computer Engineering
Organization id
51
Institution établissement
Université Laval
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2014
Competition year année de concours
2014
Award amount
22000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
1510
Committee name en
Electrical and Computer Engineering
Committee name fr
Génie électrique et informatique
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1901
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical technology
Research subject fr
Technologie biomédicale
Partie
1
Nb partie
5
Application title
Smart Medical Instrumentation On Chips For Early Detection and Treatment of Brain Molecular Disorder
Keyword
NSERC
Application summary
Major advances in medicine, drug discovery and new treatments can considerably improve the quality of life of the world population. On the other hand, new diseases are surfacing and affecting the 65 years and plus population. Most of these health problems are associated with neurodegenerative diseases, which are mainly related to a neurotransmitter (NT) concentration disorder in the brain. Alzheimer?s is one of neurodegenerative diseases that affect the largest portion of the world?s elderly population. The Alzheimer?s society of Montreal estimates that the number of patient suffering from this disease will be 34 million worldwide in 2025 and will reach a total of 750 000 patients in Canada in 2031. Up to now, there is no treatment for Alzheimer?s disease, but there are several alternatives to reduce its impact and effects. Our discovery proposal will offer hope for patients suffering from this disease by controlling the neurotransmitters (NTs) concentration in a local area of the brain in order to stop the disorder caused by Alzheimer?s using miniaturized and implantable microsystems. Indeed, NTs are among the most important information vehicles in the brain. Almost all human behavior and body functions are monitored by NTs and any disorder due to these molecules will affect our quality of life and health conditions. Our recently published results show that the electrical properties of cerebrospinal fluid (CSF) are affected by the NTs concentration. We have identified a relation between CSF impedance, conductivity and NTs concentration. Finally, we have proven with glutamate NT and gamma amino butyric acid (GABA) NT that the CSF impedance and conductivity are affected by the change of NTs concentration. As an example, Alzheimer?s disease is related to a considerable decrease of acetylcholine NT which affects CSF properties based on our previous research. Furthermore, as the concentration of NTs can be in the range of sub-nano liters, we need an extremely highly sensitive device with an accuracy of 0.001 S/m and 10 ohm to measure the conductivity and resistivity of the CSF, respectively. An innovative contribution of this work is the establishment of a new perspective for the analysis of brain neuronal activities where one assumes that NTs (acetylcholine, dopamine and GABA) can be differentiated based on their concentration, impedance and/or conductivity. If successful, this could provide an important alternative to the current treatment of patients with neurodegenerative diseases such as Alzheimer?s. We are proposing a new generation of brain implantable devices that are sensing the chemical and molecular brain activity and can also achieve neurotransmitter local delivery in order to stop brain disorder. In order to achieve this objective, we propose a medical instrumentation on-chip (MIOC) to sense and modulate NT concentration in limited area. This discovery covers the following aspects of MIOC design: 1- Development of a new fabrication process to design microelectrode for NTs sensing and manipulation and biosensing techniques for NTs based on carbon nanotubes. 2- Design and Implementation of highly sensitive microelectronics circuit to detect NT concentration change 3- Development of a new in-channel and air bubble liquid sampling technique to sample a few nano-liters of NT. Such a technique, will certainly open other alternatives to replace conventional micro pumps as it does not require any dedicated microfabrication process. The proposed MIOC can also be generalized for blood chemical and molecular disorders such as for cholesterol, sickle-cell anemia, etc. as the sensing and liquid manipulation architecture are the same while the bio-interface differs from one application to another.